{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:52:22Z","timestamp":1792083142065,"version":"4.4.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011392","name":"State Key Laboratory of Supramolecular Structure and Materials","doi-asserted-by":"publisher","award":["SKLSSM201602"],"award-info":[{"award-number":["SKLSSM201602"]}],"id":[{"id":"10.13039\/501100011392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017585","name":"First Hospital of Jilin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017585","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013284","name":"Program for Jilin University Science and Technology Innovative Research Team","doi-asserted-by":"publisher","award":["2017TD-25"],"award-info":[{"award-number":["2017TD-25"]}],"id":[{"id":"10.13039\/501100013284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31770780"],"award-info":[{"award-number":["31770780"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.tips.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:29:38Z","timestamp":1761658178000},"page":"15-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers"],"prefix":"10.1016","volume":"47","author":[{"given":"Wenju","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-0573","authenticated-orcid":false,"given":"Ming-Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-6735","authenticated-orcid":false,"given":"Lei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.09.006_bb0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41573-024-01080-6","article-title":"Targeting lysine acetylation readers and writers","volume":"24","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.09.006_bb0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","article-title":"Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets","volume":"9","author":"Qian","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.tips.2025.09.006_bb0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/biomedicines13030594","article-title":"A minireview on BET inhibitors: beyond bromodomain targeting","volume":"13","author":"Iudin","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.tips.2025.09.006_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112426","article-title":"Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery","volume":"200","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2025.09.006_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41594-024-01384-6","article-title":"Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity","volume":"32","author":"Zhang","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0035","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.09.006_bb0040","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948795","article-title":"PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition","volume":"21","author":"Wang","year":"2020","journal-title":"EMBO Rep."},{"key":"10.1016\/j.tips.2025.09.006_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2025.09.006_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112987","article-title":"Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours","volume":"191","author":"Sch\u00f6ffski","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tips.2025.09.006_bb0055","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-1429","article-title":"Phase I results of bromodomain and extra-terminal inhibitor PLX51107 in combination with azacitidine in patients with relapsed\/refractory myeloid malignancies","volume":"29","author":"Senapati","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.09.006_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2018.04.006","article-title":"Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation","volume":"151","author":"Liu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0065","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.0c00035","article-title":"Discovery of orally bioavailable chromone derivatives as potent and selective BRD4 inhibitors: scaffold hopping, optimization, and pharmacological evaluation","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0070","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/acsptsci.5c00068","article-title":"Orally bioavailable BRD4 BD1 inhibitor ZL0516 effectively suppresses colonic inflammation in animal models of inflammatory bowel disease","volume":"8","author":"Ma","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.tips.2025.09.006_bb0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12931-025-03306-6","article-title":"An orally bioavailable BRD4 inhibitor disrupts expansion of a pathogenic epithelial-mesenchymal niche in bleomycin-induced fibrosis","volume":"26","author":"Skibba","year":"2025","journal-title":"Respir. Res."},{"key":"10.1016\/j.tips.2025.09.006_bb0080","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/acs.jmedchem.1c01851","article-title":"Discovery, X-ray crystallography, and anti-inflammatory activity of bromodomain-containing protein 4 (BRD4) BD1 inhibitors targeting a distinct new binding site","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0085","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.09.006_bb0090","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.molcel.2018.06.036","article-title":"DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4","volume":"71","author":"Jin","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0095","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156657","article-title":"mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer","volume":"8","author":"Kumari","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2025.09.006_bb0100","article-title":"BRD4 binds the nucleosome via both histone and DNA interactions","author":"Zhu","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.tips.2025.09.006_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16588-8","article-title":"Structural mechanism of the oxygenase JMJD6 recognition by the extraterminal (ET) domain of BRD4","volume":"7","author":"Konuma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.09.006_bb0110","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.cell.2013.10.056","article-title":"Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release","volume":"155","author":"Liu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0115","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1186\/s12967-023-04394-y","article-title":"JMJD6-BRD4 complex stimulates lncRNA HOTAIR transcription by binding to the promoter region of HOTAIR and induces radioresistance in liver cancer stem cells","volume":"21","author":"Pei","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2025.09.006_bb0120","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1038\/s41467-019-11132-w","article-title":"JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma","volume":"10","author":"Wong","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.09.006_bb0125","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.molcel.2015.10.033","article-title":"NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler","volume":"60","author":"Shen","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0130","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1016\/j.molcel.2021.07.018","article-title":"ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency","volume":"81","author":"Cao","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13073-020-00760-3","article-title":"ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer","volume":"12","author":"Szczepanski","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.tips.2025.09.006_bb0140","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1158\/0008-5472.CAN-21-1114","article-title":"PAX9 determines epigenetic state transition and cell fate in cancer","volume":"81","author":"Zhao","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2025.09.006_bb0145","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41588-021-00934-8","article-title":"BRD4 orchestrates genome folding to promote neural crest differentiation","volume":"53","author":"Linares-Saldana","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2025.09.006_bb0150","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.molcel.2017.07.025","article-title":"The short isoform of BRD4 promotes HIV-1 latency by engaging repressive SWI\/SNF chromatin-remodeling complexes","volume":"67","author":"Conrad","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0155","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1016\/j.celrep.2019.11.114","article-title":"PCNA unloading is negatively regulated by BET Proteins","volume":"29","author":"Kang","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.09.006_bb0160","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s42003-024-05801-w","article-title":"NIPBL-mediated RAD21 facilitates tumorigenicity by the PI3K pathway in non-small-cell lung cancer","volume":"7","author":"Xu","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0165","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1158\/2159-8290.CD-21-1491","article-title":"BAF complex maintains glioma stem cells in pediatric H3K27M glioma","volume":"12","author":"Panditharatna","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.09.006_bb0170","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1093\/nar\/gkaa255","article-title":"ATAD5 deficiency alters DNA damage metabolism and sensitizes cells to PARP inhibition","volume":"48","author":"Giovannini","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2025.09.006_bb0175","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1073\/pnas.1516813113","article-title":"Structure of the Brd4 ET domain bound to a C-terminal motif from \u03b3-retroviral integrases reveals a conserved mechanism of interaction","volume":"113","author":"Crowe","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.006_bb0180","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.str.2016.04.019","article-title":"Structural mechanism of transcriptional regulator NSD3 recognition by the ET domain of BRD4","volume":"24","author":"Zhang","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.tips.2025.09.006_bb0185","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.molcel.2023.06.032","article-title":"Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation","volume":"83","author":"Zheng","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108166","article-title":"BRD4 prevents R-loop formation and transcription-replication conflicts by ensuring efficient transcription elongation","volume":"32","author":"Edwards","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.09.006_bb0195","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/0008-5472.CAN-23-2888","article-title":"KDM5C-mediated recruitment of BRD4 to chromatin regulates enhancer activation and BET inhibitor sensitivity","volume":"84","author":"Qiang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2025.09.006_bb0200","article-title":"BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer","volume":"119","author":"Liu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.006_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101326","article-title":"The intrinsic kinase activity of BRD4 spans its BD2-B-BID domains","volume":"297","author":"Weissman","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0210","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1073\/pnas.1120422109","article-title":"BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain","volume":"109","author":"Devaiah","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.006_bb0215","doi-asserted-by":"crossref","first-page":"38755","DOI":"10.1074\/jbc.M112.412015","article-title":"Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation","volume":"287","author":"Devaiah","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0220","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0225","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","article-title":"Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4","volume":"24","author":"Zanconato","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.09.006_bb0230","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1073\/pnas.1919507117","article-title":"MYC protein stability is negatively regulated by BRD4","volume":"117","author":"Devaiah","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.006_bb0235","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1016\/j.molcel.2024.09.030","article-title":"Phosphorylation by JNK switches BRD4 functions","volume":"84","author":"Devaiah","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0240","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.molcel.2023.11.022","article-title":"IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors","volume":"84","author":"Wu","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0245","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tips.2022.07.001","article-title":"Biomolecular condensates: new opportunities for drug discovery and RNA therapeutics","volume":"43","author":"Conti","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2025.09.006_bb0250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41580-024-00789-x","article-title":"Transcription regulation by biomolecular condensates","volume":"26","author":"Pei","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0255","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.molcel.2021.01.031","article-title":"Co-condensation between transcription factor and coactivator p300 modulates transcriptional bursting kinetics","volume":"81","author":"Ma","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3958","article-title":"Coactivator condensation at super-enhancers links phase separation and gene control","volume":"361","author":"Sabari","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.09.006_bb0265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41594-020-0394-8","article-title":"Roles of the BRD4 short isoform in phase separation and active gene transcription","volume":"27","author":"Han","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0270","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41421-023-00544-0","article-title":"BRD4-targeting PROTAC as a unique tool to study biomolecular condensates","volume":"9","author":"Shi","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.tips.2025.09.006_bb0275","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41467-020-20400-z","article-title":"BET inhibition disrupts transcription but retains enhancer-promoter contact","volume":"12","author":"Crump","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.09.006_bb0280","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41576-024-00780-4","article-title":"Functional specificity in biomolecular condensates revealed by genetic complementation","volume":"26","author":"Sabari","year":"2025","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.tips.2025.09.006_bb0285","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2012.12.006","article-title":"Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting","volume":"49","author":"Wu","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0290","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.celrep.2016.07.001","article-title":"BRD4 phosphorylation regulates HPV E2-mediated viral transcription, origin replication, and cellular MMP-9 expression","volume":"16","author":"Wu","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.09.006_bb0295","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/acsptsci.4c00057","article-title":"Novel BRD4-p53 inhibitor SDU-071 suppresses proliferation and migration of MDA-MB-231 triple-negative breast cancer cells","volume":"7","author":"Wang","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.tips.2025.09.006_bb0300","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114719","article-title":"I\u03baB kinase-\u03b1 coordinates BRD4 and JAK\/STAT signaling to subvert DNA damage-based anticancer therapy","volume":"42","author":"Pecharrom\u00e1n","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2025.09.006_bb0305","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/cancers12061637","article-title":"Bromodomain-containing protein BRD4 is hyperphosphorylated in mitosis","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.tips.2025.09.006_bb0310","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1038\/s41467-021-24687-4","article-title":"Stromal induction of BRD4 phosphorylation results in chromatin remodeling and BET inhibitor resistance in colorectal cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.09.006_bb0315","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41419-023-06149-5","article-title":"Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.tips.2025.09.006_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add8928","article-title":"Arginine methylation of BRD4 by PRMT2\/4 governs transcription and DNA repair","volume":"8","author":"Liu","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tips.2025.09.006_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf5374","article-title":"BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation","volume":"7","author":"Vershinin","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tips.2025.09.006_bb0330","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.molcel.2020.04.034","article-title":"Opposing functions of BRD4 isoforms in breast cancer","volume":"78","author":"Wu","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0335","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s44319-023-00033-1","article-title":"BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma","volume":"25","author":"Das","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.tips.2025.09.006_bb0340","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1021\/acsptsci.1c00159","article-title":"Development of murine leukemia virus integrase-derived peptides that bind Brd4 extra-terminal domain as candidates for suppression of acute myeloid leukemia","volume":"4","author":"Xing","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.tips.2025.09.006_bb0345","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/acs.jmedchem.4c00141","article-title":"Peptide inhibitor targeting the extraterminal domain in BRD4 potently suppresses breast cancer both in vitro and in vivo","volume":"67","author":"Huang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117767","article-title":"Discovery of a potent and selective peptide inhibitor with d-amino acids targeting the BRD4 ET domain for renal cancer therapy","volume":"294","author":"Jiang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202406414","article-title":"mRNA display in cell lysates enables identification of cyclic peptides targeting the BRD3 extraterminal domain","volume":"63","author":"Hurd","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.tips.2025.09.006_bb0360","first-page":"323","article-title":"Nuclear condensates of YAP fusion proteins alter transcription to drive ependymoma tumourigenesis","volume":"25","author":"Hu","year":"2023","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0365","article-title":"A natural product targets BRD4 to inhibit phase separation and gene transcription","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.tips.2025.09.006_bb0370","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1093\/nar\/gkad301","article-title":"Phase-separated DropCRISPRa platform for efficient gene activation in mammalian cells and mice","volume":"51","author":"Ma","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2025.09.006_bb0375","doi-asserted-by":"crossref","first-page":"26028","DOI":"10.1021\/jacs.3c06179","article-title":"Bifunctional small molecules that induce nuclear localization and targeted transcriptional regulation","volume":"145","author":"Gibson","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.tips.2025.09.006_bb0380","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1126\/science.aaz4427","article-title":"Partitioning of cancer therapeutics in nuclear condensates","volume":"368","author":"Klein","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.09.006_bb0385","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1016\/j.cell.2024.10.015","article-title":"Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders","volume":"187","author":"Lu","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0390","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17460441.2023.2187777","article-title":"Novel approaches to targeted protein degradation technologies in drug discovery","volume":"18","author":"Xue","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.tips.2025.09.006_bb0395","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.09.006_bb0400","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.006_bb0405","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13046-019-1387-5","article-title":"Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer","volume":"38","author":"Noblejas-L\u00f3pez","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.09.006_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114259","article-title":"Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold","volume":"236","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0415","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07089-6","article-title":"Targeted protein degradation via intramolecular bivalent glues","volume":"627","author":"Hsia","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.09.006_bb0420","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41589-022-01218-w","article-title":"Targeted degradation via direct 26S proteasome recruitment","volume":"19","author":"Bashore","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0425","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2025.09.006_bb0430","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0435","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","article-title":"Targeted protein degrader development for cancer: advances, challenges, and opportunities","volume":"44","author":"Fang","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2025.09.006_bb0440","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1039\/D2CS00114D","article-title":"Translational PK-PD for targeted protein degradation","volume":"51","author":"Bartlett","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.tips.2025.09.006_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107377","article-title":"BET degrader exhibits lower antiproliferative activity than its inhibitor via EGR1 recruiting septins to promote E2F1-3 transcription in triple-negative breast cancer","volume":"208","author":"Liu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2025.09.006_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103774","article-title":"RIPTACs: a groundbreaking approach to drug discovery","volume":"28","author":"Ma","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2025.09.006_bb0455","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2024.07.005","article-title":"Regulated induced proximity targeting chimeras-RIPTACs - a heterobifunctional small molecule strategy for cancer selective therapies","volume":"31","author":"Raina","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0460","doi-asserted-by":"crossref","first-page":"10503","DOI":"10.1021\/acs.jmedchem.5c01250","article-title":"RIPTACs for precision cancer therapy: a novel modality with the inspiration of HLD-0915 as the first candidate in clinical trials","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0465","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-023-06348-2","article-title":"Rewiring cancer drivers to activate apoptosis","volume":"620","author":"Gourisankar","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.09.006_bb0470","doi-asserted-by":"crossref","first-page":"14052","DOI":"10.1021\/jacs.0c05537","article-title":"Phosphorylation-inducing chimeric small molecules","volume":"142","author":"Siriwardena","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.tips.2025.09.006_bb0475","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj7251","article-title":"EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling","volume":"10","author":"Hu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tips.2025.09.006_bb0480","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1021\/jacs.2c10759","article-title":"Protein phosphatase 5-recruiting chimeras for accelerating apoptosis-signal-regulated kinase 1 dephosphorylation with antiproliferative activity","volume":"145","author":"Zhang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.tips.2025.09.006_bb0485","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3324\/haematol.2016.154013","article-title":"CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells","volume":"102","author":"Lian","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2025.09.006_bb0490","doi-asserted-by":"crossref","first-page":"9284","DOI":"10.1038\/s41598-024-60031-8","article-title":"RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma","volume":"14","author":"Jermakowicz","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.09.006_bb0495","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027","article-title":"Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer","volume":"78","author":"Shu","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0500","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.2022019306","article-title":"Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation","volume":"145","author":"Shah","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.tips.2025.09.006_bb0505","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-021-00066-9","article-title":"Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma","volume":"3","author":"Vann","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.tips.2025.09.006_bb0510","doi-asserted-by":"crossref","first-page":"17413","DOI":"10.1021\/acs.jmedchem.1c01535","article-title":"Discovery of potent and novel dual PARP\/BRD4 inhibitors for efficient treatment of pancreatic cancer","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0515","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.2c00135","article-title":"Discovery of 4-hydroxyquinazoline derivatives as small molecular BET\/PARP1 inhibitors that induce defective homologous recombination and lead to synthetic lethality for triple-negative breast cancer therapy","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0520","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200753119","article-title":"A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo","volume":"119","author":"Xiao","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.006_bb0525","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41589-019-0310-x","article-title":"Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3","volume":"15","author":"B\u00f6ttcher","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tips.2025.09.006_bb0530","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1002\/anie.201915896","article-title":"Potent dual BET\/HDAC inhibitors for efficient treatment of pancreatic cancer","volume":"59","author":"He","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.tips.2025.09.006_bb0535","doi-asserted-by":"crossref","first-page":"14620","DOI":"10.1021\/acs.jmedchem.1c01119","article-title":"4-Acyl pyrrole capped HDAC inhibitors: a new scaffold for hybrid inhibitors of BET proteins and histone deacetylases as antileukemia drug leads","volume":"64","author":"Sch\u00e4ker-H\u00fcbner","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0540","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/acs.jmedchem.2c01607","article-title":"Design, synthesis, and biological evaluation of a potent dual EZH2-BRD4 inhibitor for the treatment of some solid tumors","volume":"66","author":"Huang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0545","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1021\/acs.jmedchem.1c01876","article-title":"Design and synthesis of dual EZH2\/BRD4 inhibitors to target solid Tumors","volume":"65","author":"Guo","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.006_bb0550","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1038\/s41388-022-02327-5","article-title":"Targeting CDCP1 gene transcription coactivated by BRD4 and CBP\/p300 in castration-resistant prostate cancer","volume":"41","author":"Ji","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2025.09.006_bb0555","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1016\/j.ymthe.2022.07.022","article-title":"BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2025.09.006_bb0560","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006070","article-title":"BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors","volume":"11","author":"Fu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2025.09.006_bb0565","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41375-023-01808-0","article-title":"BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8(+) T cells","volume":"37","author":"Romine","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2025.09.006_bb0570","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/1535-7163.MCT-23-0065","article-title":"First-in-human study of AZD5153, a small-molecule inhibitor of bromodomain protein 4, in patients with relapsed\/refractory malignant solid tumors and lymphoma","volume":"22","author":"Hamilton","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2025.09.006_bb0575","article-title":"Phase IIa study of PLX2853 in gynecologic cancers with known ARID1A mutation and Phase Ib\/IIa study of PLX2853\/Carboplatin in platinum-resistant epithelial ovarian cancer","volume":"7","author":"Duska","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.tips.2025.09.006_bb0580","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12885-025-13851-4","article-title":"Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)","volume":"25","author":"Marbach","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tips.2025.09.006_bb0585","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-025-01143-2","article-title":"MYC in cancer: from undruggable target to clinical trials","volume":"24","author":"Whitfield","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.09.006_bb0590","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41467-024-45353-5","article-title":"G-quadruplexes promote the motility in MAZ phase-separated condensates to activate CCND1 expression and contribute to hepatocarcinogenesis","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.09.006_bb0595","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0600","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.96445.2","article-title":"Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer","volume":"13","author":"Wei","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.tips.2025.09.006_bb0605","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2025.09.006_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117933","article-title":"KB-0118, A novel BET bromodomain inhibitor, suppresses Th17-mediated inflammation in inflammatory bowel disease","volume":"185","author":"Jeong","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tips.2025.09.006_bb0615","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2110812119","article-title":"BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4","volume":"119","author":"Ahmed","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.006_bb0620","first-page":"E5352","article-title":"Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma","volume":"114","author":"Wang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.006_bb0625","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.celrep.2019.10.066","article-title":"The bromodomain protein 4 contributes to the regulation of alternative splicing","volume":"29","author":"Uppal","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.09.006_bb0630","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ddtec.2016.05.003","article-title":"Phospho-BRD4: transcription plasticity and drug targeting","volume":"19","author":"Chiang","year":"2016","journal-title":"Drug Discov. Today Technol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016561472500224X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016561472500224X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:52:14Z","timestamp":1777495934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016561472500224X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S016561472500224X"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.09.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting BRD4 bromodomains and beyond: exploring new therapeutic frontiers","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}